Navican Genomics is a precision medicine company focused on comprehensive cancer care. It offers testing and treatment options for actionable gene mutations, as well as next-generation sequencing. Its TheraMap solution enables users to leverage precision genomics and clinical analytics to improve patient outcomes.
Navican will use the new funds to commercialize and expand its cancer care offerings, including the TheraMap solution.
“Innovation is a top priority at Intermountain Healthcare,” said Marc Harrison, MD, president and CEO of Intermountain Healthcare. “As we develop incredible advancements that will improve healthcare outcomes, we are excited to partner with companies such as Navican to serve patients and communities around the world.”
Intermountain Healthcare led the financing round.
More articles on health IT:
VA’s most expensive task? Modernizing IT, says Shulkin
IBM: 5 insights on Watson’s oncology performance
Medicare would save $63M annually with HIEs, study finds
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
